^
    5d
    Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy. (PubMed, Theranostics)
    A co-delivery therapeutic strategy combining the pan-HDAC inhibitor belinostat (PXD101) with paclitaxel (PTX) was developed and evaluated in patient-derived cisplatin-resistant organoids and a platinum-refractory patient-derived xenograft (PDX) model. Modulation of p21 influenced cell-cycle re-entry, senescence burden, and responsiveness to PTX. These findings define an HDAC-p21-senescence axis that sustains chemoresistance in bladder cancer and provide preclinical evidence supporting combined epigenetic and antimitotic therapy as a strategy to overcome acquired drug tolerance.
    Journal
    |
    HDAC1 (Histone Deacetylase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    cisplatin • paclitaxel • Beleodaq (belinostat)
    1m
    RESOLVE: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, University of Utah | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    2ms
    Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Jul 2028 --> Dec 2028 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    Beleodaq (belinostat) • Folotyn (pralatrexate) • soquelitinib (CPI-818)
    2ms
    Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jan 2027 --> Dec 2025
    Trial primary completion date
    |
    Mektovi (binimetinib) • Beleodaq (belinostat)
    3ms
    Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic Framework. (PubMed, Biomed Chromatogr)
    Belinostat and its potential metabolites have often been qualitatively and quantitatively estimated and tracked using several analytical methods including UPLC-MS/MS, HPLC-UV, FTIR, TLC, NMR, and ESI-MS. In terms of therapeutic use of belinostat, this review demonstrates how important it is to understand the metabolism and degradation pathways of belinostat, as well as possible drug-drug interactions.
    Review • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    Beleodaq (belinostat)
    3ms
    ETCTN 10500: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    RAS wild-type • EZH2 mutation
    |
    Tazverik (tazemetostat) • Beleodaq (belinostat)
    3ms
    Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (clinicaltrials.gov)
    P2, N=15, Completed, University of Miami | Active, not recruiting --> Completed
    Trial completion
    |
    IFNA1 (Interferon Alpha 1)
    |
    cyclophosphamide • Beleodaq (belinostat)
    3ms
    ETCTN: Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jan 2027
    Trial completion date
    |
    Inqovi (decitabine/cedazuridine) • Beleodaq (belinostat) • guadecitabine (SGI-110)
    4ms
    RESOLVE: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    5ms
    Comprehensive Analysis to Reveal Nitrogen Metabolism-Associated Genes as a Prognostic Index in Head and Neck Squamous Cell Cancer. (PubMed, Curr Med Chem)
    Our study established a NM-related gene signature closely linked to immune microenvironment and drug sensitivity, highlighting potential biomarkers and therapeutic targets for prognosis and personalized therapy in HNSCC.
    Journal
    |
    SLC7A5 (Solute Carrier Family 7 Member 5) • HPRT1 (Hypoxanthine Phosphoribosyltransferase 1)
    |
    erlotinib • gefitinib • Beleodaq (belinostat)
    7ms
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) (clinicaltrials.gov)
    P3, N=218, Recruiting, Dizal Pharmaceuticals
    New P3 trial
    |
    gemcitabine • Epidaza (chidamide) • Beleodaq (belinostat) • Folotyn (pralatrexate) • golidocitinib (DZD4205)
    7ms
    Establishment of a prognostic model and immune profiling based on phagocytic regulatory genes in hepatocellular carcinoma. (PubMed, Transl Cancer Res)
    Regarding treatment, Belinostat, Dabrafenib, and Sorafenib showed higher sensitivity in the low-risk group, whereas Docetaxel demonstrated greater sensitivity in the high-risk category. This study offers a comprehensive analysis of the immune landscape characteristics and potential anticancer drugs in HCC based on PFRGs, providing valuable insights and novel perspectives for the treatment of HCC patients.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B) • NKG2D (killer cell lectin like receptor K1)
    |
    Tafinlar (dabrafenib) • sorafenib • docetaxel • Beleodaq (belinostat)